KA
MRNA icon

Klingman & Associates’s Moderna MRNA Stock Holding History

Klingman & Associates’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-2,906
Closed -$345K – 270
2024
Q2 		$345K Buy
2,906
+18
+0.6% +$2.28K 0.02% 179
2024
Q1 		$308K Sell
2,888
-965
-25% -$97.3K 0.02% 191
2023
Q4 		$383K Buy
+3,853
New +$324K 0.03% 159

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Klingman & Associates's MRNA Position: Q3 2024 in Review

Klingman & Associates sold out of Moderna (MRNA) in Q3 2024, closing a stake of 2,906 shares — an estimated $345K sold.

Klingman & Associates first reported a position in MRNA in Q4 2023 and held it in 3 quarters. The position peaked at $383K in Q4 2023. 788 funds tracked by Wall St. Rank hold MRNA as of Q3 2024.

  • Klingman & Associates reported no remaining Moderna position as of Q3 2024 after selling out during the quarter.
  • Klingman & Associates sold 2,906 Moderna shares in Q3 2024, an estimated $345K.
  • Klingman & Associates first reported a position in Moderna in Q4 2023 and held it in 3 quarters.
  • Klingman & Associates's Moderna position peaked at $383K in Q4 2023.
  • 788 funds tracked by Wall St. Rank held Moderna as of Q3 2024.

Based on Klingman & Associates's 13F filing for Q3 2024, filed 1 Nov 2024.